How The FDA Can Compel Post-Marketing Studies
The U.S. Food and Drug Administration announced in the Federal Register on April 1 the availability of a draft guidance for industry titled "Post-Marketing Studies and Clinical Trials — Implementation of...To view the full article, register now.
Already a subscriber? Click here to view full article